American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (986)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (940)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1255)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (311)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (62)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5172)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HMGA1 chromatin regulators disrupt 3D genome architecture and chromatin looping to repress MHC II genes and drive immune evasion during MPN progression
    Meeting Abstract

    Resar, L.; Kim, J.; Supreme, A. A.; Woo, H.; West, B.; Antopia, M. C.; Thompson, Z.; Reddy, K.; Kim, J. H.; Cope, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase II study of longitudinal geriatric assessment with risk-adapted interventions to reduce non-relapse mortality in allogeneic hematopoietic cell transplantation for older patients with advanced myeloid malignancies
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Brown, S.; Hanley, D. M.; Engstler, D. E.; Politikos, I.; Gyurkocza, B.; Tamari, R.; Papadopoulos, E. B.; Saldia, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African ancestry compared with those having European ancestry
    Meeting Abstract

    Maclachlan, K. H.; Papadimitriou, M.; Blaney, P.; Shekarkhand, T.; Chu, T. R.; Poos, A. M.; Brown, E.; Hoering, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The Composite Health Risk Assessment Model (CHARM) predicts risks of toxicities, functional and cognitive decline among survivors of allogeneic hematopoietic cell transplantation (allo-HCT): A prospective BMT-CTN study 1704
    Meeting Abstract

    Sorror, M.; Saber, W.; Logan, B. R.; Geller, N.; Bellach, A.; Kou, J.; Wood, W. A.; McCarty, J. M.; Knight, T. G.; Runaas, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; GarceĢs, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): Preliminary results from the CA057-003 trial
    Meeting Abstract

    Costa, L. J.; Schjesvold, F.; Popat, R.; Siegel, D.; Usmani, S. Z.; Ali, S. A.; Chu, M. P.; Hartley-Brown, M. A.; Bahlis, N. J.; Oriol, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1b study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
    Meeting Abstract

    Gangat, N.; Foran, J. M.; Halpern, A. B.; Rampal, R.; Bose, P.; Hexner, E. O.; Talpaz, M.; Michaelis, L. C.; Islam, P.; Swords, R. T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of response to hypomethylating agent-based therapy on survival outcomes in the context of baseline clinical-molecular risk and transplant status in patients with myelodysplastic syndromes/neoplasms (MDS): An analysis from the international consortium for MDS (icMDS) validate database
    Meeting Abstract

    Rolles, B.; Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stempel, J. M.; Lanino, L.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, showed durable clinical response and sustained hematological improvement in relapsed/refractory myelofibrosis patients
    Meeting Abstract

    El Chaer, F.; Rein, L. A. M.; Yuda, J.; Shimoda, K.; Takami, A.; Ichii, M.; McCloskey, J.; Scandura, J. M.; Iurlo, A.; Bose, P.; more...
    Blood (2024)

    Fulltext@MSK | Save